Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate‐salt hypertensive uni‐nephrectomized KKA y mice-Reference-Cited by-同舟云学术

Ameliorative effect of phosphodiesterase 4 and 5 inhibitors in deoxycorticosterone acetate‐salt hypertensive uni‐nephrectomized KKA y mice

Published:2020-09-16 Issue:11 Volume:34 Page:14997-15014
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Nio Yasunori¹,Ookawara Mitsugi¹,Yamasaki Midori¹,Hanauer Guido²,Tohyama Kimio³,Shibata Sachio³,Sano Tomoya⁴,Shimizu Fumi⁴,Anayama Hisashi⁴,Hazama Masatoshi¹,Matsuo Takanori¹

Affiliation:

1. Extra‐Value Generation and General Medicine DDU Takeda Pharmaceutical Company Limited Fujisawa Japan

2. Takeda Pharmaceuticals International AGTakeda Pharmaceutical Company Limited Fujisawa Japan

3. Drug Metabolism & Pharmacokinetics Research Laboratories Takeda Pharmaceutical Company Limited Fujisawa Japan

4. Drug Safety Research Laboratories Takeda Pharmaceutical Company Limited Fujisawa Japan

Funder

Takeda Pharmaceutical Company

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.202001084R

Reference46 articles.

1. Novel effective drugs for diabetic kidney disease? or not?

2. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage

3. Mechanisms of Tubulointerstitial Fibrosis

4. Cellular and molecular mechanisms of renal fibrosis

5. Have we reached the limits for the treatment of diabetic nephropathy?

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostaglandin E2 (PGE2) and Roflumilast Involvement in IPF Progression;International Journal of Molecular Sciences;2023-08-03

2. Phosphodiesterase 4 inhibitors in diabetic nephropathy;Cellular Signalling;2022-02

3. Clinical Implication of Phosphodiesterase-4-Inhibition;International Journal of Molecular Sciences;2022-01-21

4. Protective effect of a novel phosphodiesterase 4 selective inhibitor, compound A, in diabetic nephropathy model mice;European Journal of Pharmacology;2021-03